Amalgamated Financial’s Regeneron Pharmaceuticals REGN Stock Holding History

Amalgamated Financial’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$19.4M	Buy	+27,835	New	+$17.6M	0.15%	100

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Amalgamated Financial's REGN Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Regeneron Pharmaceuticals (REGN) in Q1 2022: 27,835 shares worth $19.4M. The stake represents 0.15% of the portfolio and ranks #100 among its holdings.

1,095 funds tracked by Wall St. Rank hold REGN as of Q1 2022.

Amalgamated Financial held 27,835 shares of Regeneron Pharmaceuticals worth $19.4M as of Q1 2022.
Regeneron Pharmaceuticals was a new Amalgamated Financial position in Q1 2022.
Regeneron Pharmaceuticals made up 0.15% of Amalgamated Financial's portfolio in Q1 2022, its #100 holding.
1,095 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.